Abstract

413P - RX-3117, a novel hypomethylating agent, shows promising therapeutic activity in combination with nab-paclitaxel and check-point inhibitors in preclinical models

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer
Tina C Lavranos ... Daniel Inglis
Molecular Cancer Therapeutics | VOL. 14
Tina C Lavranos, et. al.Tina C Lavranos ... Daniel Inglis
01 Dec 2015
Abstract 1573: Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models
Che-Leung Law ... Priyanka E Basak
Cancer Research | VOL. 81
Che-Leung Law, et. al.Che-Leung Law ... Priyanka E Basak
01 Jul 2021
Abstract P248: The tyrosine kinase inhibitor XL092 promotes an immune-permissive tumor microenvironment and enhances the anti-tumor activity of immune checkpoint inhibitors in preclinical models
Ted Yun ... Peter Lamb
Molecular Cancer Therapeutics | VOL. 20
Ted Yun, et. al.Ted Yun ... Peter Lamb
01 Dec 2021
Abstract 1754: Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models
Dajun Yang ... Miaoyi Wu
Cancer Research | VOL. 78
Dajun Yang, et. al.Dajun Yang ... Miaoyi Wu
01 Jul 2018
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers